Delaware | 33-0728374 | |
(State or other jurisdiction of | (IRS Employer | |
incorporation) | Identification No.) |
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
The information with respect to item 2.02 in this current report and its accompanying exhibit shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this current report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Dynavax, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Exhibit No. Description
99.1 Press Release, dated August 4, 2009 titled "Dynavax Announces Second Quarter 2009 Financial Results."
99.2 Press Release, dated August 4, 2009 titled "Dynavax Announces Path for HEPLISAV(TM) Hepatitis B Vaccine Development."
Dynavax Technologies Corporation | ||||||||
Date: August 04, 2009 | By: | /s/ Deborah A. Smeltzer | ||||||
Deborah A. Smeltzer | ||||||||
Vice President, Operations & Chief Financial Officer | ||||||||
Exhibit No. | Description | |
EX-99.1 | Press Release, dated August 4, 2009 titled "Dynavax Announces Second Quarter 2009 Financial Results." | |
EX-99.2 | Press Release, dated August 4, 2009 titled "Dynavax Announces Path for HEPLISAV(TM) Hepatitis B Vaccine Development." |